Zusamenfassung
Brustkrebs ist die häufigste Krebserkrankung der Frauen in Deutschland. 10% erkranken lebenslang, das mittlere Erkrankungsalter liegt bei 65 Jahren. Bei einer kleinen Gruppe von Frauen liegt das Erkrankungsrisiko jedoch sehr viel höher: Sie erkranken zu 85% mit einem mittleren Erkrankungsalter von 45 Jahren. Die allgemeinen Präventionsmaßnahmen sind in dieser Hochrisikogruppe nicht ausreichend.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Antionou et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117–1130
Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. JCO 2008; 26(26): 4282–4288
Brekelmans CT, Seynaeve C, Bartels CC et al. (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19: 924–30
Graeser MK, Engel C, Rhiem K, Gadziki D, Bick U, Kast K, Froster UG, Schlehe B, Bechthold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK. Contralateral breast cancer risk in BRCA1 and BRCA2 muation carriers. JCO 2009, epub ahead of print.
Kauff ND, Satagopan JM, Robson ME, et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609–15
King MC, Wieand S, Hale K et al. (2001)Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251–6
Kollias J, Sibbering DM, Blamey RW (1998) Screeening women aged less than 50 years with a family history of breast cancer. Eur J Cancer 34: 878–883
Kriege M, Brekelmans CTM, Boetes C, et al. (2004) Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition: New England Journal of Medicine 351: 427–437
Kuhl CK, Schmutzler RK, Leutner CC et al. (2000) Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215: 267–79
Meijers-Heijboer H., van Geel B, van Putten WL et al. (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345: 159–64
Metcalfe K, Lynch HT, Ghadirian P, et al. (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncology 22: 2328–35
Metcalfe KA, Finch A, Poll A, Horsmann D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA (2009) Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 100: 421–425
Miki Y, Swensen J, Shattuck-Eidens D et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71
Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedmann E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24(16): 2437–43
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Van’t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade Ol, Weber BL (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncology 22(6): 1055–1062
Rhiem K, Flucke U, Schmutzler RK (2005) BRCA1-associated breast carcinomas frequently present with benign sonographic features. Am J Roentgenol 184(4)1260–1265
Robson ME, Chappuis PO, Satagopan J, et al. (2003) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research 6: R8–R17
Tilanus-Linthorst MMA, Alves C, Seynaeve C, Menke-Pluymers MBE, Eggermont AMM, Brekelmans CTM (2006) Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer. Br J Surg 93: 961–968
Tilanus-Linthorst MM Verhoog L Obdeijn IM Barthels K Menke-Pluymers M Eggermont A Klijn J Meijers-Heijboer H Van der Kwast T Brekelmans C 2002 A BRCA1/2 mutation high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102 91–95
Wooster R, Bignell G, Lancaster J et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg New York
About this chapter
Cite this chapter
Schmutzler, R., Kast, K. (2010). Familiäres Mammakarzinom — Beratung und Betreuung betroffener Familien. In: Mammakarzinom Interdisziplinär. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12681-9_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-12681-9_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12680-2
Online ISBN: 978-3-642-12681-9
eBook Packages: Medicine (German Language)